Varian Medical Systems and Elekta Settle Patent Litigation
Get Alerts VAR Hot Sheet
Join SI Premium – FREE
PALO ALTO, Calif., April 3, 2017 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced that it has reached a confidential settlement agreement with Elekta (EKTA-B) to end ongoing patent litigation involving technology used for radiation oncology and the treatment of cancer. Varian and Elekta resolved the multi-year disputes in the United States, Germany, and the United Kingdom, including the suit brought by Elekta AB and William Beaumont Hospital, with no payments exchanged by the plaintiffs and defendants and no future financial obligations. The two companies have been in litigation since 2015.
About Varian Medical SystemsVarian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,400 people at sites around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Press Contact Spencer SiasVarian Medical Systems+1 (650) 424-5782 [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/varian-medical-systems-and-elekta-settle-patent-litigation-300433725.html
SOURCE Varian Medical Systems
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sonar Sciences Launches Platform for Testing and Publishing Algorithmic Trading Strategies
- Thor Explorations Announces Further High-Grade Mineralisation Intersected Below Segilola Open Pit
- Oma Savings Bank Plc to publish its Half-Year Financial Report Report for January-June 2026 and hold a webcast on 13 August 2026
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share